Humanized Monoclonal Anti-CD3 Antibody Visilizumab As Second-Line Therapy For Glucocorticoid-Refractory, Acute GVHD
Phase of Trial: Phase II
Latest Information Update: 06 Jan 2014
At a glance
- Drugs Visilizumab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors PDL BioPharma
- 06 Jan 2014 Status changed from active, no longer recruiting to discontinued.
- 09 Feb 2006 New trial record.